Published online Sep 30, 2008.
https://doi.org/10.4048/jbc.2008.11.3.116
Correlation between the Her-2/neu Status as Determined by Immunohistochemical Analysis and the Serum Her-2/neu Concentration as Determined by the Use of ADVIA Cencaur® Automated Immunoassay in Breast Cancer Patients
Abstract
Purpose
Serum Her-2/neu is extracted from the extracelluar domain of the Her-2/neu tyrosine kinase to serum. We evaluated the correlation between the Her-2/neu status as determined by immunohistochemical analysis (IHC) and the serum Her-2/neu concentration in a population of Korean women with breast cancer.
Methods
Serum Her-2/neu levels were examined from 254 female patients with primary breast cancer and 38 patients with metastatic breast cancer. Serum Her-2/neu levels were measured by the use of a chemiluminescence immunoassay (ADVIA centaur® system) during the preoperative period. The level of Her-2/neu in all of the breast cancer tissue samples was determined by IHC, and samples with an IHC grade +2 were subject to fluorescence in situ (FISH). When tissue samples exhibited IHC grade +3 or showed amplification of Her-2/neu as determined by FISH analysis, Her-2/neu was considered overexpressed. The cut-off value for serum Her-2/neu level was 10.2 ng/mL.
Results
The mean serum Her-2/neu level was 10.1 ng/mL in primary breast cancer samples. The serum Her-2/neu concentration significantly correlated with expression of Her-2/neu as determined by tissue IHC analysis (grade 1/3, 9.33±1.7 ng/mL; grade 2/3, 8.89±1.6 ng/mL; grade 3/3, 12.37±4.0 ng/mL, p<0.001). Increased serum HER-2/neu levels were associated with the lymph node status (p=0.003) and hormone unresponsiveness (p<0.001), tumor size (p<0.01) and age group (p<0.001). In metastatic breast cancer samples, the mean serum Her-2/neu level was 13.6 ng/mL. Elevated serum Her-2/neu levels were seen in 71.7% of metastatic breast cancer samples. The serum Her-2/neu level correlated with expression of Her-2/neu in metastatic tissue as determined by IHC analysis (p<0.001) rather than with the Her-2/neu status of the primary breast cancer (p=0.16)
Conclusion
Serum Her-2/neu appears to be correlate with tissue Her-2/neu expression in primary and metastatic breast cancer where Her-2/neu is overexpressed. Further studies to determine levels of serum Her-2/neu are required to determine cuttoff values and the clinical application of the finding for breast cancer patients in Korea.
Fig 1
Distribution of serum Her-2/neu in primary breast cancer patients.
Fig 2
Distribution of serum Her-2/neu according to tissue Her-2/neu analysis (IHC) with grade 0/3 (n=117), grade 1/3 (n=44), grade 2/3 (n=33), and grade 3/3 (n=60). The means (SD) were as fellows: grade 0/3, 9.5 (1.7) ng/mL; grade 1/3, 9.3 (1.7) ng/mL; grade 2/3, 8.8 (1.6) ng/mL; grade 3/3, 12.3 (4.0) ng/mL. There was significant difference between groups (p<0.001).
Fig 3
ROC curve of serum Her-2/neu ECD concentration for differentiation of tissue Her-2/neu overexpression. AUC for serum Her-2/neu ECD was 0.73 (95% confidence interval; 0.66-0.80).
Fig 4
Serum Her-2/neu ECD concentration according to tissue Her-2/neu status in 18 patients with metastatic breast cancer with grade 0/3 (n=4), grade 1/3 (n=6), grade 2/3 (n=1), and grade 3/3 (n=8). The means (SD) were as follows: grade 0/3, 10.9 (1.8) ng/mL; grade 1/3, 11.13 (3.7) ng/mL; grade 2/3, 13.9 ng/mL; grade 3/3, 40.2 (16.1) ng/mL. There was significant difference between groups (p<0.001).
Table 1
Clinicopathologic finding of primary breast cancer
Table 2
Correlation between serum Her-2/neu concentration and Her-2/neu status (IHC)
Table 3
Distribution of tissue Her-2/neu overexpression according to cuttoff value
Table 4
Correlation of serum Her-2/neu concentration and clinicopathologic variables
Table 5
Correlation of Serum Her-2/neu concentration according to tumor subtype
Table 6
Comparison of Her-2/neu status (IHC) between primary breast cancer and metastatic site with serum Her-2/neu
References
-
Ross JS, Fletcher JA. The Her-2/neu oncogene in breast cancer: prognostic factor, predicitve factor, and target for therapy. Stem Cell 1998;16:413–428.
-
-
Ali SA, Leitzel K, Chinchilli VM, Engle L, Demers L, Harvey HA, et al. Relationship of serum Her-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem 2002;48:1314–1320.
-
-
Harris LN, Liotcheva V, Broadwater G, Ramirez MJ, Maimonis P, Anderson S, et al. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 2001;19:1698–1706.
-
-
Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA, et al. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer. Clin Cancer Res 2001;7:2703–2711.
-
-
Yamauchi H, O'Neil A, Gelman R, Carney W, Tenny D, Hosch S, et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracelluar domain of the HER-2/c-neu protein. J Clin Oncol 1997;15:2518–2525.
-
-
Classen S, Kopp R, Possinger K, Weidenhagen R, Eiermann W, Wilmanns W. Clinical relevance of soluble c-erbB2 for patients with metastatic breast cancer predicting the response to second line hormone or chemotherapy. Tumor Biol 2002;23:70–75.
-
-
Muller V, Witzel I, Pantel K, Krenkel S, Luck HJ, Neumann R, et al. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer. Anticancer Res 2006;26:1479–1487.
-
-
Mehta RR, McDermott JH, Heiken TJ, Marler KC, Patel MK, Wild LD, et al. Plasma c-erbB2 levels in breast cancer patients: Prognostic significance in predicting response to chemotherapy. J Clin Oncol 1998;16:2409–2491.
-
-
Schoendorf T, Hoopmann M, Warm M, Neumann R, Thomas A, Gohring UJ, et al. Serologic concentrations of HER-2/neu in breast cancer patients with visceral metastasis receiving trastuzumab therapy predict the clinical course. Clin Chem 2002;48:1360–1362.
-
-
Hoopmann M, Neumann R, Tanasale T, Schondorf T. HER-2/neu determination in blood plasma of patients with HER-2/neu overexpressing metastatic breast cancer; a longitudinal study. Anticancer Res 2003;23:1031–1034.
-
-
Kim JW, Kim SY, Lee HS, Woo HD, Son DM, Lim CW, et al. Establishment for reference range of serum Her-2/neu in Korean healthy women. J Breast Cancer 2006;9:301–308.
-
-
Cook GB, Neaman IE, Goldblatt JL, Cambetas DR, Hussain M, Luftner D, et al. Clinial utility of serum Her-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. Anticancer Res 2001;21:1465–1470.
-
-
Anderson TI, Paus E, Nesland JM, McKenzie SJ, Borresen AL. Detection of c-erbB2 related protein in sera from breast cancer patients. Acta Oncologica 1995;34:499–504.
-
-
Molina R, Jo J, Filella X, Zanon G, Pahisa J, Munoz M, et al. C-erb B2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis. Anticancer Res 1996;16:2295–2300.
-